Cor Vasa 2004, 45(12):597-600

Levosimendan as a novel emerging favorite in the management of heart failure.

Stanislav Janoušek
Interní kardiologická klinika, Fakultní nemocnice Brno, Brno, Česká republika

The calcium sensitizer levosimendan is a new promising positive inotropic class drug for the treatment of heart failure with a beneficial effect on the hemodynamics, symptoms and short- as well as long-term prognosis of patients. In addition to improved contractility, its beneficial effects include vasodilatation (both in the coronary bed improving myocardial perfusion and in the peripheral circulation improving afterload) and, hence, cardiac performance. Another advantage is its good tolerability with a low incidence of undesirable effects and the simplicity of infusion administration. The expanding indications of levosimendan use in clinical practice are discussed.

Keywords: Heart failure; Systolic dysfunction; Calcium sensitizers; Levosimendan; New indication

Published: December 1, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janoušek S. Levosimendan as a novel emerging favorite in the management of heart failure. Cor Vasa. 2004;45(12):597-600.
Download citation




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.